AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 104 min read$STTK

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs (NASDAQ: STTK) priced a public offering of 10,879,376 shares at $4.00 each and pre-funded warrants for up to 7,870,624 shares at $3.9999 each, with a $0.0001 exercise price. Gross proceeds are expected at about $75 million before underwriting costs. The deal is set to close June 11, 2026, with a 30-day option for 2,812,500 additional shares.

Original reporting
manilatimes.net
Published Jun 10, 2026, 6:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 6:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering — source image
Source · manilatimes.net
Decision brief

The 30-second read

$STTKBearishMed
01

Why it matters

The priced offering creates immediate dilution/overhang risk while supplying ~$75M gross proceeds to fund operations and development.

02

Market read

A concrete, priced equity raise (with warrant terms) is a direct driver of near-term trading dynamics for STTK.

03

What to watch

Pre-funded warrants with near-zero exercise price can increase effective share supply; watch for underwriter option exercise and any subsequent secondary selling/hedging.

Relevance 9/10Novelty 9/10Timing: offering priced June 10; expected close June 11

Background

Shattuck is a clinical-stage biotech developing DR3 blocking antibodies (SL-325) and announced a priced follow-on equity offering.

Company-level read

Ticker impact

$STTKBearishHigh confidence
Context

Shattuck Labs priced a $75M public offering of 10,879,376 shares plus pre-funded warrants, with immediate exercisability for warrants.

Expected impact

Near-term downside bias on dilution/overhang; relief possible if proceeds are viewed as funding key clinical milestones.

Evidence & confidence

The article discloses the offering size, pricing, share/warrant counts, and immediate exercisability—core inputs for dilution and supply overhang.

Market effects

Sector

Reinforces ongoing capital-raising needs in clinical-stage biotech; may modestly affect sentiment/read-through for similarly sized DR3/immune-modulation peers.

Regional

Limited; company-specific financing event with no stated regional spillover.

Global

Low; US-listed issuer with SEC-registered offering mechanics.

Counterpoint

What could challenge this read

If the market interprets the $75M as sufficient to de-risk upcoming clinical catalysts, the offering could be absorbed quickly and reduce future financing risk.

Key entities

  • issuer
    Shattuck Labs, Inc.

    Clinical-stage biotech that priced a $75M public offering of common stock and pre-funded warrants.

  • bookrunner
    Leerink Partners

    Joint bookrunning manager for the offering.

  • bookrunner
    J.P. Morgan

    Joint bookrunning manager for the offering.

  • bookrunner
    Piper Sandler

    Joint bookrunning manager for the offering.

  • bookrunner
    Cantor Fitzgerald

    Joint bookrunning manager for the offering.

Read at source← All news

Related articles

AUG 12
$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

investing.com4 min
AUG 11
$STTKMed

Shattuck Labs, Inc. (STTK): Results of Operations and Financial Condition

Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sttk_2q2026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism i

SEC EDGAR 8-K6 min
AUG 11
$STTKMed

Why is Shattuck Labs stock slipping today?

Shattuck Labs (STTK) shares fell 1.8% pre-open after its Q2 2026 earnings. The company reported a net loss of $15.2 million versus $12.5 million a year earlier, and R&D rose 34% to $11.7 million. It cited favorable Phase 1 safety for SL-325 and said Phase 2b in Crohn’s is on track. Cash and investments were about $208.3 million.

investing.com5 min
AUG 11
$STTKMedAI 8/10

Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Shattuck Labs (NASDAQ: STTK) reported Q2 2026 results and clinical updates for SL-325 and SL-846. SL-325 Phase 1 showed a favorable safety profile, 3.7% antidrug antibodies, and durable TL1A/DR3 blockade; RECEPTIVE-CD1 Phase 2b in Crohn’s is expected to start Q3 2026. Cash and investments were $208.3M, funding operations into 2029.

finanznachrichten.de7 min
JUL 25
$STTKMed

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

Shattuck Labs shares rose about 4.8% on Friday, closing near $7.43. The move followed an inaugural note from JPMorgan’s Brian Cheng, who rated STTK overweight and set a $10 price target. The note cited Shattuck’s lead IBD drug candidate SL-325, referencing recent healthy volunteer data on safety and target engagement.

fool.com3 min
JUN 10
$STTKMedAI 8/10

Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr

Shattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and said it will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant. The company expects about $75 million in gross proceeds and said the deal should close June 11. Underwriters have a 30-day option for up to 2.81 million additional shares.

rttnews.com2 min